Sequana Medical announces the results of
27 May 2021, 06: 00 pm THISST
Ghent, BELGIUM – 27 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic water overload resistant to liver disease, malignant ascites and heart failure, today announces that all the proposed resolutions submitted to the Annual and Extraordinary General Meeting of Shareholders have was approved at the meetings held today at 9:00 a.m. CEST.
The items on the agenda of the general meetings included the approval of a number of resolutions relating to the financial year ended December 31, 2020, as well as the reappointment of the directors and the statutory auditor, the approval of a certain number of changes to the control clauses, the issuance of a new stock option plan and the renewal of the authorization to the Board of Directors to increase the share capital within the framework of the authorized capital.
The minutes of the general meetings, as well as the revised versions of the Company’s articles of association, are available on the Company’s website.
For more information please contact:
Director of Investor Relations
Phone: +32 498 05 35 79
E-mail: [email protected]
Guillaume van Renterghem
Phone: +41 76 735 01 31
E-mail: [email protected]
About Sequana Medical
Sequana Medical is a commercial stage medical device company using its property alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for water overload in liver diseases, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a common complication of many important diseases, including advanced liver disease due to cirrhosis and heart failure related to NASH (nonalcoholic steatohepatitis), with resistance to diuretics being widespread. The American market for alfaThe pump resulting from NASH-related cirrhosis is expected to exceed € 3 billion per year over the next 10 to 20 years. The heart failure market for RSD and the alfaThe DSR® pump is estimated at more than 5 billion euros per year in the United States and the EU5 by 2026.
the alfaThe pump is a unique, fully implanted, cordless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally removed through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through the use of sodium-free infusate delivered to the abdominal cavity.
In the United States, the company’s main growth market, the alfaThe FDA has granted the pump a revolutionary device designation for relapsing or refractory ascites due to cirrhosis of the liver. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive results against all of the primary endpoints of the study. This study aims to support a future marketing application of the alfapump in the United States and Canada. In Europe, the alfaThe pump is CE marked for the management of refractory ascites due to cirrhosis of the liver and malignant ascites and is included in major clinical practice guidelines. Over 850 alfapumping systems have been installed to date.
Sequana Medical has combined its alfaexclusive DSR pump and therapy, and develops the alfapump DSR, a revolutionary approach to water overload due to heart failure. RED DESERT, the repeated dose alfaThe pump DSR study in patients with heart failure resistant to diuretics demonstrated that repeated treatment with DSR is able to both manage the water and sodium balance in these patients as well as restore their diuretic response and ” improve their cardio-renal condition.
Sequana Medical is headquartered in Ghent, Belgium. For more information, please visit www.sequanamedical.com.
Important Regulatory Disclaimers
the alfapump® is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® is currently under clinical investigation (POSEIDON study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information on the POSEIDON clinical study, see www.poseidonstudy.com. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy come from ongoing preclinical and clinical investigations that have yet to be completed. DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between DSR® therapy and ongoing investigations with the alfapump® in Europe, the United States or Canada.
To note: alfapump® is a registered trademark. DSR® and alfapump DSR® are trademarks registered in the Benelux.
Press release_AGM EGM results_27 May 2021_DUTCH_vF
Press release_AGM EGM results_27 May 2021_ENGLISH_vF